Display options
Cite
Holt DE, Gill BS, Clump DA, et al. Tumor bed radiosurgery following resection and prior stereotactic radiosurgery for locally persistent brain metastasis. Front Oncol. 2015;5:84doi: 10.3389/fonc.2015.00084.
Holt, D. E., Gill, B. S., Clump, D. A., Leeman, J. E., Burton, S. A., Amankulor, N. M., Engh, J. A., & Heron, D. E. (2015). Tumor bed radiosurgery following resection and prior stereotactic radiosurgery for locally persistent brain metastasis. Frontiers in oncology, 584. https://doi.org/10.3389/fonc.2015.00084
Holt, Douglas Emerson, et al. "Tumor bed radiosurgery following resection and prior stereotactic radiosurgery for locally persistent brain metastasis." Frontiers in oncology vol. 5 (2015): 84. doi: https://doi.org/10.3389/fonc.2015.00084
Holt DE, Gill BS, Clump DA, Leeman JE, Burton SA, Amankulor NM, Engh JA, Heron DE. Tumor bed radiosurgery following resection and prior stereotactic radiosurgery for locally persistent brain metastasis. Front Oncol. 2015 Apr 08;5:84. doi: 10.3389/fonc.2015.00084. eCollection 2015. PMID: 25905042; PMCID: PMC4389371.
Copy Download .nbib Format: NLM
Share it on

Front Oncol. 2015 Apr 08;5:84. doi: 10.3389/fonc.2015.00084. eCollection 2015.

Tumor bed radiosurgery following resection and prior stereotactic radiosurgery for locally persistent brain metastasis.

Frontiers in oncology

Douglas Emerson Holt, Beant Singh Gill, David Anthony Clump, Jonathan E Leeman, Steven A Burton, Nduka M Amankulor, Johnathan Anderson Engh, Dwight E Heron

Affiliations

  1. Department of Radiation Oncology, University of Pittsburgh Cancer Institute , Pittsburgh, PA , USA.
  2. Department of Radiation Oncology, University of Pittsburgh Cancer Institute , Pittsburgh, PA , USA ; Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center , New York, NY , USA.
  3. Department of Neurological Surgery, University of Pittsburgh Medical Center , Pittsburgh, PA , USA.

PMID: 25905042 PMCID: PMC4389371 DOI: 10.3389/fonc.2015.00084

Abstract

PURPOSE: Despite advances in multimodality management of brain metastases, local progression following stereotactic radiosurgery (SRS) can occur. Often, surgical resection is favored, as it frequently provides immediate symptom relief as well as pathological characterization of any residual tumor. Should the pathological specimen contain viable tumor cells, further radiation therapy is an option to sterilize the tumor bed. We evaluated the use of repeat SRS (rSRS) in lieu of whole-brain radiation therapy (WBRT) as a means of improving local control (LC) while minimizing potential toxicity and dose to the normal brain.

MATERIALS/METHODS: A retrospective review was performed to identify patients with brain metastases who underwent SRS and then surgical resection for locally recurrent or persistent disease. From 2004 to 2014, 13 consecutive patients or 15 lesions were treated with rSRS after resection, either post-operatively to the tumor bed (n = 10, 66.6%) or after a second local recurrence (n = 5, 33.3%). LC, distant brain failure (DBF), and radiation toxicity were determined using patient records, RECIST criteria v1.1, and CTCAE v4.03.

RESULTS: At a median follow-up interval of 9.0 months (range 1.8-54.9 months) from time of rSRS, five patients remain alive. Following rSRS, 13 of the 15 (86.6%) lesions were locally controlled with an estimated 100% LC at 6 months and 75% LC at 1 year. However, 11 of the 15 (73.3%) treated lesions developed DBF after rSRS with 3 of 13 patients proceeding to WBRT. Two of 15 (13.3%) resulted in either grade 2 radionecrosis with grade 3 seizures or grade 3 radionecrosis.

CONCLUSION: Repeat SRS represents a potential salvage therapy for patients with locally recurrent brain metastases, providing additional tumor control with acceptable toxicity, even in the setting of prior SRS and surgical resection. rSRS may be reasonable to use as an alternative to WBRT in this setting.

Keywords: brain metastases; cyberknife; radiosurgery; re-irradiation; recurrence

References

  1. J Neurooncol. 2010 Jan;96(1):85-96 - PubMed
  2. Int J Radiat Oncol Biol Phys. 2007 Aug 1;68(5):1388-95 - PubMed
  3. Cancer Chemother Pharmacol. 1992;30(4):251-60 - PubMed
  4. Neurosurg Clin N Am. 1996 Jul;7(3):337-44 - PubMed
  5. Radiat Oncol. 2013 Jun 07;8:135 - PubMed
  6. Neurol Sci. 2011 Jun;32(3):393-9 - PubMed
  7. Lancet Oncol. 2009 Nov;10(11):1037-44 - PubMed
  8. Tohoku J Exp Med. 2011;223(2):125-31 - PubMed
  9. J Neurooncol. 2005 Oct;75(1):5-14 - PubMed
  10. J Neurooncol. 2010 Jan;96(1):45-68 - PubMed
  11. Int J Radiat Oncol Biol Phys. 2000 May 1;47(2):291-8 - PubMed
  12. Neurosurgery. 2000 Apr;46(4):860-6; discussion 866-7 - PubMed
  13. Int J Radiat Oncol Biol Phys. 2008 May 1;71(1):64-70 - PubMed
  14. Oncology (Williston Park). 1999 Jul;13(7):941-54, 957-61; discussion 961-2, 9 - PubMed
  15. Acta Neurochir (Wien). 2004 Sep;146(9):989-93; discussion 993 - PubMed
  16. Br J Cancer. 2010 Mar 16;102(6):995-1002 - PubMed
  17. J Radiat Res. 2014 Mar 1;55(2):334-42 - PubMed
  18. Int J Radiat Oncol Biol Phys. 2002 Jul 1;53(3):527-32 - PubMed
  19. Eur J Cancer. 2009 Jan;45(2):228-47 - PubMed
  20. J Neurooncol. 1996 Mar;27(3):287-93 - PubMed
  21. Radiat Oncol. 2014 Oct 17;9:231 - PubMed
  22. Stereotact Funct Neurosurg. 1999;72 Suppl 1:73-80 - PubMed
  23. J Chemother. 2004 Nov;16 Suppl 5:94-7 - PubMed
  24. Radiology. 1967 Feb;88(2):322-5 - PubMed
  25. Br J Radiol. 1981 Sep;54(645):782-6 - PubMed
  26. Ann Oncol. 1999 Jul;10(7):753-9 - PubMed
  27. Neurosurg Clin N Am. 1996 Jul;7(3):527-36 - PubMed
  28. Oncologist. 2004;9(1):68-79 - PubMed
  29. N Engl J Med. 1990 Feb 22;322(8):494-500 - PubMed
  30. Clin Neurol Neurosurg. 2007 Feb;109(2):132-7 - PubMed
  31. Lung Cancer. 2004 Nov;46(2):255-61 - PubMed

Publication Types

Grant support